The comparison of cyclopentolate and atropine in patients with refractive accommodative esotropia by means of retinoscopy, autorefractometry and biometric lens thickness.
OBJECTIVE
In this study, we aimed to compare the cycloplegic effect of cyclopentolate HCI 1% and atropine sulphate 1% in patients with refractive accommodative esotropia by means of retinoscopy, autorefractometer and the measurement of lens thickness by biometry.


METHODS
Thirty-two patients with refractive accommodative esotropia aged from 5 to 10 (mean 6.8+/-1.4), had a deviation under 10 prism diopters, and underwent retinoscopic, autorefractometric and biometric study in dry and wet conditions.


RESULTS
The retinoscopic, autorefractometric and biometric findings of the right eye were 5.10+/-1.21 diopter (D), 5.03+/-1.20 D, 3.43+/-0.16 mm with cyclopentolate, and 5.2+/-1.2 D, 5.2+/-1.2 D, 3.4+/-0.1 mm with atropine. In the left eye, the measurements were 5.2+/-1.4 D, 5.1+/-1.4 D, 3.5+/-0.2 mm with cyclopentolate, and 5.3+/-1.2 D, 5.20+/-1.3 D, 3.4+/-0.2 mm with atropine, respectively. When these obtained data were compared by the Student's t test no statistical significance was found (p > 0.05).


CONCLUSIONS
We suggest that the cyclopentolate cycloplegia applied to the patients with refractive accommodative esotropia is sufficient to produce good cycloplegia, with an effect similar to atropine.
Celebi
S
S
Department of Ophthalmology, Firat University, Elaziğ, Turkey.
Aykan
U
U
D000065:Accommodation, Ocular / Q000187:drug effects*; D001285:Atropine / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003519:Cyclopentolate / Q000008:administration & dosage / Q000627:therapeutic use*; D004948:Esotropia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007908:Lens, Crystalline / Q000187:drug effects / Q000473:pathology*; D008297:Male; D009184:Mydriatics / Q000008:administration & dosage / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D011680:Pupil / Q000187:drug effects; D012029:Refraction, Ocular / Q000187:drug effects*; D014792:Visual Acuity
D009184:Mydriatics; D009883:Ophthalmic Solutions; D001285:Atropine; D003519:Cyclopentolate